维普期刊资源整合服务平台（V6.5）

101篇 您的检索式：作者名="Donowitz"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases显示文摘The introduction of biologics such as anti-tumor necrosis factor(TNF)monoclonal antibodies followed by anti-integrins has dramatically changed the therapeutic paradigm of inflammatory bowel diseases(IBD).Furthermore,a newly developed anti-p40 subunit of interleukin(IL)-12 and IL-23(ustekinumab)has been recently approved in the United States for patients with moderate to severe Crohn’s disease who have failed treatment with anti-TNFs.However,these immunosuppressive therapeutics which focus on anti-inflammatory mechanisms or immune cells still fail to achieve long-term remission in a significant percentage of patients.This strongly underlines the need to identify novel treatment targets beyond immune suppression to treat IBD.Recent studies have revealed the critical role of intestinal epithelial cells(IECs)in the pathogenesis of IBD.Physical,biochemical and immunologic driven barrier dysfunctions of epithelial cells contribute to the development of IBD.In addition,the recent establishment of adult stem cell-derived intestinal enteroid/organoid culture technology has allowed an exciting opportunity to study human IECs comprising all normal epithelial cells.This long-term epithelial culture model can be generated from endoscopic biopsies or surgical resections and recapitulates the tissue of origin,representing a promising platform for novel drug discovery in IBD.This review describes the advantages of intestinal enteroids/organoids as a research tool for intestinal diseases,introduces studies with these models in IBD,and gives a description of the current status of therapeutic approaches in IBD.Finally,we provide an overview of the current endeavors to identify a novel drug target for IBD therapy based on studies with human enteroids/organoids and describe the challenges in using enteroids/organoids as an IBD model.	Jun-Hwan Yoo Mark Donowitz	2019	World Journal of Gastroenterology2019，25，30：	8
2	The burden of selected digestive diseases in the United States显示文摘	Robert S. sandler James E. Everhart Mark Donowitz Elizabeth Adams Kelly Cronin Clifford Goodman Eric Gemmen Shefali Shah Aida Avdic Robert Rubin	2002	Gastroenterology2002，，5：	2
3	Caspofungin versus liposomal amphoteriein B for empirical antifungal therapy in patients with persistent fever and neutropenia显示文摘	Walsh TJ Teppler H Donowitz GR		0，，：	1
4	The burden of selected digestive diseases in the United States 显示文摘	Sandier RS Everhart JE Donowitz M	2002	Gastroenterology2002，122，5：	1
5	Nontypable haemophilus influenzae meningitis显示文摘	Cuthill SL Farley MMD Donowitz LG	1999	Pediatr Infect Dis1999，18，7：	1
6	Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia显示文摘	Walsh TJ Teppler H Donowitz GR	2004	N Eng J Med2004，35，14：	1
7	The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria evidence for long survival of Acinetobacter calcoaceticus 显示文摘	Getchell-White S1 Donowitz LG Groschel DH	1989	Infect Control Hosp Epidemiol1989，10，：	1
8	Evolutionary origins of eukaryotic sodium/proton exchangers显示文摘	BRETT C L DONOWITZ M RAO R	2005	American Journal of Physiolo gy-Cell Physiology2005，288，2：	1
9	The burden of selected digestive diseases in the United States显示文摘	Sandier RS Everhart JE Donowitz M	2002	Gastroenterology2002，，122：	1
10	Caspofunginversus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia 显示文摘	Walsh T J Teppler H Donowitz G R	2004	J New Engl Medicine2004，351，14：	1
11	The burden of selected digestive diseases in the United States显示文摘	Sandier RS Everhart JE Donowitz M	2002	Gastroenterology2002，122，11：	1
12	Hyperthermia effects on cytosolic:analysis at the single cell level by digitized imaging microscopy and cell survival显示文摘	MIKKELSEN R B REINLIB L DONOWITZ M	1991	Cancer Research1991，51，1：	1
13	The burden of selected digestive diseases in the United States 显示文摘	Sandier RS Everhart JE Donowitz M	2002	Gastroenterology2002，122，5：	1
14	NHERF family and NHE3 regulation显示文摘	DONOWITZ M CHA B ZACHOS N C	2005	J Physiol2005，567，：	1
15	Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia 显示文摘	Walsh TJ Teppler H Donowitz GR	2004	N Engl J Med2004，315，：	1
16	Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia显示文摘	Walsh TJ Teppler H Donowitz GR	2004	N Engl J Med2004，351，14：	1
17	Molecular physiology of intestinal Na^+/H^+ exchange显示文摘	Zachos NC Tse M Donowitz M	2005	Annu Rev Physiol2005，67，：	1
18	Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia显示文摘	Walsh TJ Teppler H Donowitz GR	2004	N Engl J Med2004，351，14：	1
19	Caspofungin ver- sus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia 显示文摘	Walsh T J Teppler H Donowitz GR	2004	N Engl J Med2004，351，14：	1
20	Caspofungin versus liposomal amphoteriein B for empirical antifungal therapy in patients with persistent fever and neutropenia 显示文摘	Walsh T J Teppler H Donowitz G R	2004	NEJM2004，351，12：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示